Lv719
4410 积分 2023-05-08 加入
The evolving landscape of obesity pharmacotherapy
12天前
已完结
Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond
15天前
已完结
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
15天前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
15天前
已完结
Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity
16天前
已完结
A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates
16天前
已完结
Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists
16天前
已完结
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
21天前
已完结
FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance
22天前
已完结
CD98 at the crossroads of adaptive immunity and cancer
28天前
已完结
皖公网安备34019202002308
